These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

251 related items for PubMed ID: 25181403

  • 1. The clinical effectiveness of pegylated interferon and ribavirin for the treatment of chronic hepatitis C in HIV-infected patients in Brazil: a multicentric study.
    Ferreira PR, Silva MH, Brandão-Melo CE, Rezende RE, Gonzalez M, Reuter T, Urbaez JD, Gianini RJ, Martinelli A, Mendes-Correa MC.
    Braz J Infect Dis; 2015; 19(1):15-22. PubMed ID: 25181403
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Antiviral regimen complexity index as an independent predictor of sustained virologic response in patients with chronic hepatitis C.
    Galán RJ, Cidoncha EC, Martin MF, Rodriguez CC, Almeida CV, Verdugo RM.
    J Manag Care Pharm; 2013; 19(6):448-53. PubMed ID: 23806058
    [Abstract] [Full Text] [Related]

  • 4. Therapeutic effectiveness of biosimilar standard interferon versus pegylated interferon for chronic hepatitis C genotypes 2 or 3.
    Vigani AG, Gonçales ES, Pavan MH, Genari F, Tozzo R, Lazarini MS, Fais V, Feltrin A, Gonçales NS, Gonçales FL.
    Braz J Infect Dis; 2012; 16(3):232-6. PubMed ID: 22729189
    [Abstract] [Full Text] [Related]

  • 5. Pegylated interferon plus ribavirin in HIV-infected patients with recurrent hepatitis C after liver transplantation: a prospective cohort study.
    Castells L, Rimola A, Manzardo C, Valdivieso A, Montero JL, Barcena R, Abradelo M, Xiol X, Aguilera V, Salcedo M, Rodriguez M, Bernal C, Suarez F, Antela A, Olivares S, Del Campo S, Laguno M, Fernandez JR, de la Rosa G, Agüero F, Perez I, González-García J, Esteban-Mur JI, Miro JM, FIPSE LT-HIV Investigators.
    J Hepatol; 2015 Jan; 62(1):92-100. PubMed ID: 25127748
    [Abstract] [Full Text] [Related]

  • 6. Cytopenias during treatment of HIV-HCV-coinfection with pegylated interferon and ribavirin: safety analysis of the OPERA study.
    Pontali E, Angeli E, Cattelan AM, Maida I, Nasta P, Verucchi G, Caputo A, Iannacone C, Puoti M.
    Antivir Ther; 2015 Jan; 20(1):39-48. PubMed ID: 24831457
    [Abstract] [Full Text] [Related]

  • 7. [Alpha-interferon versus peg-interferon associated to ribavirin in the treatment of genotype 1 hepatitis C virus and human immunodeficiency virus coinfected patients].
    Almeida PR, Tovo CV, Rigo JO, Zanin P, Alves AV, Mattos AA.
    Arq Gastroenterol; 2009 Jan; 46(2):132-7. PubMed ID: 19578615
    [Abstract] [Full Text] [Related]

  • 8. Effect of aging, glucose level, and HIV viral load on response to treatment with pegylated interferon plus ribavirin in HIV/HCV co-infected women.
    Nasta P, Maida I, Cattelan AM, Pontali E, Angeli E, Giralda M, Verucchi G, Caputo A, Iannacone C, Puoti M, Carosi G.
    J Womens Health (Larchmt); 2015 Feb; 24(2):159-64. PubMed ID: 25682817
    [Abstract] [Full Text] [Related]

  • 9. Peginterferon plus ribavirin and sustained virological response rate in HCV-related advanced fibrosis: a real life study.
    Silva GF, Villela-Nogueira CA, Mello CE, Soares EC, Coelho HS, Ferreira PR, Ruiz FJ, Brazilian HCV-Related Advanced Fibrosis Study Group.
    Braz J Infect Dis; 2014 Feb; 18(1):48-52. PubMed ID: 24055310
    [Abstract] [Full Text] [Related]

  • 10. Sustained virological response to pegylated interferon plus ribavirin leads to normalization of liver stiffness in hepatitis C virus-infected patients.
    Macías J, Rivero A, Cifuentes C, Camacho A, Neukam K, Rivero-Juárez A, Mira JA, Torre-Cisneros J, Gómez-Mateos J, Pineda JA.
    Enferm Infecc Microbiol Clin; 2013 Feb; 31(7):424-9. PubMed ID: 23453582
    [Abstract] [Full Text] [Related]

  • 11. Retreatment of hepatitis C patients with pegylated interferon combined with ribavirin in non-responders to interferon plus ribavirin. Is it different in real life?
    Gonçales FL, Moma CA, Vigani AG, Angerami AF, Gonçales ES, Tozzo R, Pavan MH, Gonçales NS.
    BMC Infect Dis; 2010 Jul 20; 10():212. PubMed ID: 20646277
    [Abstract] [Full Text] [Related]

  • 12. Analysis of variables and interactions among variables associated with a sustained virological response to pegylated interferon alfa-2a plus ribavirin in hepatitis C virus genotype 3-infected patients.
    Aziz H, Raza A, Waheed Y, Gill U, Gill ML.
    Int J Infect Dis; 2012 Aug 20; 16(8):e597-602. PubMed ID: 22658873
    [Abstract] [Full Text] [Related]

  • 13. Comparison of high ribavirin induction versus standard ribavirin dosing, plus peginterferon-α for the treatment of chronic hepatitis C in HIV-infected patients: the PERICO trial.
    Labarga P, Barreiro P, da Silva A, Guardiola JM, Rubio R, Aguirrebengoa K, Miralles P, Portu J, Téllez MJ, Morano L, Castro A, Pineda JA, Terrón A, Hernández-Quero J, Mariño A, Ríos MJ, Echeverría S, Asensi V, Vispo E, Soriano V, PERICO Study Group.
    J Infect Dis; 2012 Sep 15; 206(6):961-8. PubMed ID: 22807523
    [Abstract] [Full Text] [Related]

  • 14. Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C.
    Furusyo N, Ogawa E, Nakamuta M, Kajiwara E, Nomura H, Dohmen K, Takahashi K, Satoh T, Azuma K, Kawano A, Tanabe Y, Kotoh K, Shimoda S, Hayashi J, Kyushu University Liver Disease Study (KULDS) Group.
    J Hepatol; 2013 Aug 15; 59(2):205-12. PubMed ID: 23542346
    [Abstract] [Full Text] [Related]

  • 15. Hepatitis C virus therapy with peg-interferon and ribavirin in Myanmar: A resource-constrained country.
    Hlaing NK, Banerjee D, Mitrani R, Arker SH, Win KS, Tun NL, Thant Z, Win KM, Reddy KR.
    World J Gastroenterol; 2016 Nov 21; 22(43):9613-9622. PubMed ID: 27920482
    [Abstract] [Full Text] [Related]

  • 16. Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial.
    Sulkowski M, Pol S, Mallolas J, Fainboim H, Cooper C, Slim J, Rivero A, Mak C, Thompson S, Howe AY, Wenning L, Sklar P, Wahl J, Greaves W, P05411 study investigators.
    Lancet Infect Dis; 2013 Jul 21; 13(7):597-605. PubMed ID: 23768747
    [Abstract] [Full Text] [Related]

  • 17. [Association between ribavirin plasma concentration and sustained virologic response in treatment of patients with genotype 1b chronic hepatitis C with pegylated interferon-α-2b and ribavirin].
    Wang MR, Zhang X, Yang ZG, Li P, Gao L, Chen XH, Wang J, Xiong X, Wang SM, Geng JB, Hao KY, Xie F, Wang M, Zheng WK.
    Zhonghua Gan Zang Bing Za Zhi; 2016 Mar 20; 24(3):175-80. PubMed ID: 27095759
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of pegylated interferon plus ribavirin in HIV and hepatitis C virus-coinfected patients with advanced immunosuppression.
    Mira JA, Gutiérrez-Valencia A, Gil Ide L, Merino D, Rivero A, Ríos-Villegas MJ, Delgado M, González-Serrano M, Collado A, Torres-Tortosa M, Omar M, López-Ruz MA, Macías J, Arponen S, Pineda JA.
    Clin Infect Dis; 2009 Oct 15; 49(8):e84-91. PubMed ID: 19772388
    [Abstract] [Full Text] [Related]

  • 19. Rate and predictors of success in the retreatment of chronic hepatitis C virus in HIV/hepatitis C Virus coinfected patients with prior nonresponse or relapse.
    Labarga P, Vispo E, Barreiro P, Rodríguez-Novoa S, Pinilla J, Morello J, Martín-Carbonero L, Tuma P, Medrano J, Soriano V.
    J Acquir Immune Defic Syndr; 2010 Mar 15; 53(3):364-8. PubMed ID: 20101191
    [Abstract] [Full Text] [Related]

  • 20. Safety and Efficacy of Combined Treatment with Pegylated Interferon Alpha-2b and Ribavirin for HCV Genotype 4 in Children.
    El-Karaksy HM, Mogahed EA, El-Raziky MS, Saleh D, Besheer M, Mubarak S.
    J Interferon Cytokine Res; 2016 Jan 15; 36(1):1-8. PubMed ID: 26406390
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.